Xilis provides an end‑to‑end platform that generates patient‑derived 3D micro‑organoids (MOS®) preserving tissue heterogeneity for drug testing. The system automates high‑throughput model production, supports modular phenotypic and immune assays, and applies AI‑driven analytics to deliver quantitative efficacy and safety predictions via a secure cloud dashboard. It serves pharmaceutical, biotechnology, CRO and academic customers needing scalable, high‑fidelity preclinical models.
Funding
$19.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Preclinical drug testing often relies on cell lines or animal models that do not faithfully recapitulate human tissue complexity, leading to low predictive power, high attrition rates, and prolonged timelines for oncology and other therapeutic areas. Researchers lack scalable, patient‑derived 3D models that can be generated quickly and interrogated with flexible assay formats.
Solution
Xilis delivers an end‑to‑end platform built around its MicroOrganoSpheres (MOS®) technology, which creates three‑dimensional, patient‑derived ex vivo organoid models that retain the native cellular composition of primary tissues. The platform automates model generation, supports customizable functional assays, and applies AI‑driven analytics to translate assay readouts into quantitative efficacy and safety predictions. By providing rapid, high‑fidelity readouts across discovery, lead optimization, and clinical‑trial de‑risking stages, the solution shortens development cycles and improves decision confidence for multiple therapeutic modalities, including immuno‑oncology, chemotherapy, and cell‑based therapies. Results are delivered through a secure cloud interface that offers visualizations, statistical summaries, and exportable data formats for downstream integration.
Target Audience
The primary customers are pharmaceutical and biotechnology companies, as well as contract research organizations and academic labs, that require functional, patient‑derived models to evaluate drug candidates across oncology and other disease programs.
Features
- MOS® micro‑organoid fabrication that preserves tissue heterogeneity and microenvironmental cues
- Fully automated workflow for high‑throughput generation of 3D patient‑derived models
- Modular assay library enabling phenotypic, cytotoxicity, immune‑cell interaction, and biomarker readouts
- AI‑powered analytics pipeline that quantifies drug response, predicts clinical efficacy, and suggests patient‑selection strategies
- Cloud‑based dashboard with real‑time data visualization, trend analysis, and API access for LIMS/EHR integration
- Scalable infrastructure supporting single‑sample projects to large‑cohort studies across diverse indications
- Secure, HIPAA‑compliant data storage with role‑based access controls and end‑to‑end encryption